Two months after launching Pep2Tango Therapeutics, VC firm Versant Ventures is unveiling another obesity-focused biotech in ...

Helicore, which is developing a GIP-blocking antibody, is the fourth obesity drug developer to receive funding from Versant ...

A/S, a global healthcare giant specializing in diabetes care and obesity treatment, continues to dominate the GLP-1 drug market alongside competitor Eli Lilly (NYSE:LLY). With a market capitalization ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

US-based pharmaceutical giant Eli Lilly is focusing on weight loss medications like Mounjaro (tirzepatide), which has proven ...

Weight-loss medicines such as Ozempic might raise a person’s likelihood of developing conditions including arthritis.

A Medscape survey found that a strong majority of physicians believe high-risk patients should have easier access to new weight loss drugs.

BioAge Labs is returning to its aging roots after a failed attempt in obesity R&D. To get the ball rolling again, the biotech has entered into a multi-year research collaboration worth up to $550 ...

Structure Therapeutics, Inc. Sponsored ADR (GPCR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst ...

The company is advancing its RNA medicines platform with a promising pipeline ... treatment settings, supporting potential broad use. In preclinical studies using a mouse model of diet induced ...

BT: Are there other drugs in Eli Lilly’s pipeline targeting obesity or related conditions that we can expect in the near future? VG: India is an important market for Lilly. We are committed to ...